Two doses of the recombinant zoster vaccine, given two months apart, cause a strong increase in protective antibodies against the virus that causes shingles in people aged 50 and older in India, with...

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial.

Randomized Controlled Trial

Human

2025 Mar 19

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial.

Score: 73

DOI: 10.1016/j.vaccine.2025.126819